Product Details
| Product Name:
CU-CPT22 |
CAS No.:
1416324-85-0 |
| Purity:
99.80% |
Supply Ability:
10g |
| Release date:
2026/07/27 |
Product Introduction
Bioactivity
| Name | CU-CPT22 |
| Description | CU-CPT22 is the first probe for the complex between toll-like receptors TLR1 and TLR2. CU-CPT22 binds at the interface of TLR1 and TLR2 (IC50 = 0.58 μM). It competes with the synthetic triacylated lipoprotein (Pam3CSK4) binding to TLR1/2 (Ki: 0.41 μM). |
| In vitro | A novel compound (CU-CPT22) that can compete with the synthetic triacylated lipoprotein (Pam3CSK4) binding to TLR1/2 with high inhibitory activity and specificity.CU-CPT22 is a toll-like inhibitor of receptor 1 and 2 (TLR1/2) ( IC50: 0.58±0.09 μM).?CU-CPT22 is found to have no significant cytotoxicity at various concentrations up to 100 μM in RAW 264.7 cells.?It is showed that CU-CPT22 is able to compete with Pam3CSK4 for binding to TLR1/2 (Ki: 0.41±0.07 μM).?Which is consistent with its potency observed in the whole cell assay.?Increasing the concentration of CU-CPT22 to 6 μM decreases the anisotropy to background levels.?It is found that CU-CPT22 inhibits TLR1/2 signaling without affecting other TLRs, showing it is highly selective in intact cells.??The result shows that CU-CPT22 can inhibit about 60% of TNF-αand 95% of IL-1β at 8 μM[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 125 mg/mL (344.95 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 4 mg/mL (11.04 mM), Sonication is recommended.
|
| Keywords | Toll-like Receptor (TLR) | TLR2/1 | TLR1/2 | TLR | Inhibitor | inhibit | CU-CPT-22 | CU-CPT22 | CUCPT22 | CU CPT22 |
| Inhibitors Related | Hydroxychloroquine | Benzyl alcohol | (±)-Naringenin | Chloroquine phosphate | Chloroquine | Chloranil | CU-115 | Thiamine hydrochloride | 2,4,5-Trimethoxybenzoic acid | Resiquimod | Stevioside | DHBP |
| Related Compound Libraries | Highly Selective Inhibitor Library | Bioactive Compound Library | Anti-Alzheimer's Disease Compound Library | Membrane Protein-targeted Compound Library | HIF-1 Signaling Pathway Compound Library | Antioxidant Compound Library | Pyroptosis Compound Library | Multi-Target Compound Library | Inhibitor Library | Immuno-Oncology Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$5.00
|
VIP1Y
|
Yiwu Jingpinhui Plastic Co., Ltd.
|
2026-08-03 |
|
|
$12.00
|
VIP2Y
|
Wuhan Kejiefeng Trading Co.,Ltd
|
2026-07-23 |
|
|
|
|
Shanghai Yimeixin Technology Co., LTD
|
2026-06-23 |
United States